CTHRC1 Human, HEK

Collagen Triple Helix Repeat Containing 1 (CTHRC1) is a protein encoded by the CTHRC1 gene in humans. This protein is known for its involvement in various physiological and pathological processes, including vascular remodeling, bone formation, and morphogenesis. The recombinant form of this protein, produced in Human Embryonic Kidney (HEK) cells, is used in research to study its functions and potential therapeutic applications.

CTHRC1 was first identified in adventitial fibroblasts and neointimal smooth muscle cells of injured arteries. It is a secreted extracellular matrix protein with a molecular weight of approximately 28-30 kDa. The protein contains a collagen triple helix repeat domain, which is crucial for its structural integrity and function. This domain allows CTHRC1 to interact with other extracellular matrix components and cell surface receptors, facilitating its role in tissue remodeling and repair .

CTHRC1 plays a significant role in vascular remodeling by promoting cell migration and limiting collagen synthesis. It is involved in the regulation of the extracellular matrix, which is essential for maintaining tissue homeostasis and integrity. The protein has been shown to enhance the proliferation and migration of endothelial cells, contributing to angiogenesis and the formation of new blood vessels .

In addition to its role in vascular remodeling, CTHRC1 is implicated in bone formation and morphogenesis. It promotes osteoblast differentiation and bone matrix production, making it a potential target for therapeutic interventions in bone-related disorders .

CTHRC1 has been associated with various pathological conditions, including cancer and fibrosis. Overexpression of CTHRC1 has been observed in several types of cancers, where it acts as an oncogene promoting tumor growth and metastasis. The protein’s involvement in the Wnt signaling pathway, a key regulator of cell proliferation and differentiation, further underscores its significance in cancer biology .

In fibrosis, CTHRC1 contributes to the excessive deposition of extracellular matrix components, leading to tissue scarring and impaired organ function. Targeting CTHRC1 in fibrotic diseases holds promise for developing novel therapeutic strategies .

The recombinant form of CTHRC1, produced in HEK cells, is widely used in research to study its biological functions and therapeutic potential. HEK cells provide a suitable system for producing recombinant proteins with post-translational modifications similar to those in human cells, ensuring the protein’s functionality and stability.

Research on CTHRC1 continues to uncover its diverse roles in health and disease. Understanding the molecular mechanisms underlying its functions will pave the way for developing targeted therapies for conditions such as cancer, vascular diseases, and fibrosis .